Fig. 2
From: A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma
Clinical Performance of Methylation Markers for Detecting HCC. (A) AUC analysis of HCC-specific diagnostic markers across four different HCC validation datasets (GSE54503, GSE56588, GSE60753, and GSE89852). The x-axis denotes 1-specificity, the y-axis indicates sensitivity, and the line represents the receiver operating characteristic (ROC) curve for each dataset. (B) Boxplot illustrating left) the combined methylation scores for RNF135 and LDHB, as well as right) log20(AFP), across four groups: Healthy, At-risk, Early-stage HCC, and Late-stage HCC. A dotted line marks the 90th quantile of the at-risk group’s sum of methylation score. Log20(AFP) set at 1, based on an AFP cutoff of 20 ng/mL, is used as the cutoff value for the AFP tests. (Statistical P values are shown as *, P ≤ 0.05 and ****, P ≤ 0.0001). (C) Assay performance table for the MS-HRM and AFP tests. Sensitivity, specificity, and accuracy metric for cancers in the early (BCLC stage 0-A), late (BCLC stage B-D), and any stage are shown. (D) ROC curve for the dual-marker combination for 304 HCC patients versus 207 at-risk subjects. The color represents the following combinations: (1) AFP + AFP-L3 (black), (2) AFP + glypican-3 (GPC3) (orange), (3) AFP + MS-HRM (green), (4) AFP-L3 + GPC3 (purple), (5) AFP-L3 + MS-HRM (blue), (6) GPC3 + MS-HRM (red). The x-axis and y-axis represent 1-specificity and sensitivity, respectively